Randomized human endocrine/metabolic trial

What the research examines

Tesamorelin, a GHRH analogue, was studied in adults with abdominal obesity and reduced GH secretion. Researchers measured visceral and subcutaneous adipose tissue separately, along with IGF-I and metabolic markers.

Potential research applications

Research topics include pituitary-axis modulation and differences between adipose compartments in a defined study population.

These are research questions drawn from the cited work, not established applications of this supplied material.

Evidence limits

The cited trial involved a specific clinical formulation and selected participants. It is not evidence for general-purpose fat reduction or the equivalence of this supplied material.

Material identity and presentation

Powder vial artwork is conceptual; actual form and packaging unverified. Published findings do not establish the identity, purity or performance of an individual supplied material.